Multifactorial Intervention in Type 2 Diabetes - Italy
This trial is active, not recruiting.
|Condition||type 2 diabetes|
|Sponsor||University of Parma|
|Collaborator||Italian Society of Diabetology|
|Start date||January 2002|
|End date||December 2011|
|Trial size||1461 participants|
|Trial identifier||NCT01240070, MINDIT2000|
Despite several clinical trials have clearly demonstrated that the correction of a single cardiovascular risk factor in patients with type 2 diabetes decreases the incidence of myocardial infarction and other cardiovascular disease (CVD) events, only the Steno study has been evaluating the effect of a multifactorial intervention strategy on macrovascular complications of diabetes. For this reason, the disease management approach currently endorsed by international guidelines (i.e correction of all major CVD risk factors to target levels usually lower than lower risk populations) has not been extensively investigated in terms of prevalence of application in current clinical practice and in terms of real efficacy.
The Multifactorial INtervention in type 2 Diabetes - ITaly (MIND.IT) is a multicentric two-phase study involving 9 Diabetes Care Units throughout Italy with the overall aims of: (1) investigating the degree of application of the international guidelines for CVD prevention in type 2 diabetic patients and (2) verifying whether the application of an intensive multi-factorial intervention inspired by these guidelines is feasible and effective in decreasing the incidence of new CVD events.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Bari, Italy||Francesco Giorgino||no longer recruiting|
|Carrara, Italy||Maria Dolci||no longer recruiting|
|La Spezia, Italy||Lamberto De Giorgio||no longer recruiting|
|Pavia, Italy||Giuseppe Derosa||no longer recruiting|
|Perugia, Italy||PierPaolo DeFeo||no longer recruiting|
|Piacenza, Italy||Donatella Zavaroni||no longer recruiting|
|Pisa, Italy||Roberto Miccoli||no longer recruiting|
|Roma, Italy||Giovanni Ghirlanda||no longer recruiting|
|Torino, Italy||Mariela Trovati||no longer recruiting|
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
time frame: 5 years of follow up
cardiovascular risk factors changes
time frame: 2 years and 5 years of follow up
Male or female participants from 50 years up to 70 years old.
Inclusion Criteria: - Both genders - age 50-70 years - Type two diabetes with at least two-year history of disease and without insulin treatment in the first two years after diagnosis - Negative medical history for documented previous cardiovascular events or macrovascular complications - Written consent to participate - Presence of at least 2 of the following risk factors: - LDL cholesterol > 130 mg/dL (regardless of treatment) - Triglycerides > 200 mg/dL - HDL cholesterol < 35 (males) or 45 (females) mg/dL - Blood pressure > 140/90 mmHg - Cigarette smoking Exclusion Criteria: - Age below 50 or above 70 years - Type 1 diabetes, diagnosis before 40 years of age, known presence of auto-antibodies or insulin requirement in the first 2 years of disease. - Chronic kidney failure (plasma creatinine > 2 mg/dL) - Significant liver damage (AST and/or ALT > 2 times the upper limits of normality) - History of previous cardiovascular events - Active neoplasms or any concomitant disease limiting life expectancy
|Official title||Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes|
|Description||The study is multi-centric, randomized, open label, active treatment controlled, two parallel-group, pragmatical intervention trial with 5 years of follow-up, to assess superiority of an intensive treat-to-target strategy (including lifestyle and pharmacological interventions) for correction of major cardiovascular risk factors compared to usual care in decreasing incidence of first cardiovascular events in non complicated type 2 diabetic patients at high risk, as defined by presence of 2 or more cardiovascular risk factors. All high-risk patients identified during phase 1 who accepted to participated were allocated to usual or intensive treatment based on the recruiting center. Centers were randomly assigned to treatment arm before phase 2 beginning. Investigators from Intensive Care centers received centralized training to ensure the application of the intensive care program on their patients. HbA1c values and lipid profile are assessed in peripheral laboratories (one per each study site) with an external, centralized, quality control program and the adjustment for systematic differences among study labs. Participating investigators are left free to decide upon patient's treatments. In intensive-care centers, investigators are provided with a multi-factorial step-wise protocol to support the application of a treat-to-target approach. Intensive care strategy includes intervention on lifestyle. Dietary intervention goals: BMI<25 or 5% reduction of body weight; dietary assumption of saturated fat <10% of total caloric intake; fibers= 15-20 g/1000 Kcal. Methods defined to reach the dietary goal: A) Patients with BMI 25-30 kg/m2: reduction of caloric intake = 300-500 Cal/d; B) Patients with BMI >30: reduction of caloric intake 500-800 Cal/d. Physical activity intervention goal: 200-300 calories per day. Example: brisk walking for 30 min every day or biking (18-25Km/h 45-60 min). Alternatives: swimming 1h , dancing 1h, gym exercise 1h;-avoiding isometric exercise and exercise with intensity >50-60 % of maximal oxygen consumption. Frequency: everyday or at least 3 times a week; Pharmacological intervention: Blood glucose control, multi-step intervention. In obese patients: 1) Metformin (M, 500-2500mg); 2) M+Sulphonylureas (S) or S-like drugs, increasing progressively the dose; 3) M+S+Acarbose; 4) M+S+insulin bed-time; 5) insulin basal-bolus. In normal weight patients: 1) S; 2) S+acarbose; 3) S+ bed-time insulin; 4) insulin basal bolus; Blood pressure control --> 1) Ace-inhibitors or AT-II receptor antagonists; 2) add long acting calcium-channel blockers or beta-blockers or low dose diuretics; 3) add a third drug; lipid control: 1) diet + physical activity; 2) if LDL > 130 mg/dL statins (with a stepwise increase of dose if necessary); if triglycerides > 200 mg/dL fibrates; anti-platelet treatment: aspirin 100 mg/d in all patients (alternative drugs for aspirin-intolerants). The scheduled visits were defined as follows: - Intensive-care group: mandatory visit every three months with annual visit for MIND.IT data collection. - Usual-care group: at least one MIND.IT visit every year + the usual organization of the center.|
Call for more information